Robert J. Motzer, MD

Pictured: Robert Motzer

I am a board-certified medical oncologist who is dedicated to improving the lives of patients with genitourinary tumors. My primary area of expertise is kidney cancer (renal cell carcinoma) and testicular cancer (germ-cell tumor). For more than 25 years, I have used my skills as a clinician to provide high-quality and compassionate care for cancer patients at Memorial Sloan Kettering.

In addition to providing patients with the highest standard of medical care, I have led more than 50 clinical trials in patients with kidney cancer and testicular cancer, including national and international multicenter clinical trials. My research has helped to identify five targeted drugs — sunitinib (Sutent®), pazopanib (Votrient®), axitinib (Inlyta®), temsirolimus (Torisel®),  and everolimus (Afinitor®) — as effective treatments for patients with advanced kidney cancer. Also, I developed a system to aid in the prediction of treatment outcomes for patients taking medications for advanced kidney cancer; this (“MSKCC”) risk system is widely applied by physicians internationally to direct the care of patients. In the area of testicular cancer, my patient care and research efforts focus on developing better treatments for patients with difficult-to-treat tumors.

Appointments for New Patients
Clinical Expertise

Kidney Cancer; Germ Cell Tumors; Testicular Cancer; Autologous Bone Marrow Transplantation; Immunotherapy

Languages Spoken

MD, University of Michigan Medical School


North Shore University Hospital; Memorial Sloan Kettering Cancer Center


Memorial Sloan Kettering Cancer Center; The New York Hospital/Cornell Medical Center

Board Certifications

Internal Medicine; Medical Oncology

Publications by Robert J. Motzer
Visit PubMed for full listing of Robert J. Motzer journal articles
Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.